Europa Biosite has announced a new strategic distribution partnership with Quantoom Biosciences, a leading manufacturer of innovative mRNA technologies for global healthcare advancement supporting next generation vaccines and therapeutics. The agreement provides access to Quantoom’s pioneering research RNA production solutions for scientists across Europe.
Under the partnership, Europa Biosite will distribute Quantoom’s Ntensify® mano and Ntensify® micro technology, designed for rapid and qualitative RNA production in research settings. The collaboration is expected to broaden to include Ncapsulate® LNP formulation kits as these technologies become available to the research market.
Europa Biosite is recognized for building high-quality supplier relationships and delivering advanced reagents and technologies to academic, biotech, and pharmaceutical laboratories through its pan-European distribution network. The addition of Quantoom’s RNA production portfolio strengthens Europa Biosite’s offering in the rapidly expanding RNA research field.
José Castillo, CEO of Quantoom Biosciences commented “Europa Biosite has built an impressive reputation for connecting innovative technologies with leading research laboratories across Europe,”. He added “By joining forces, we make high-quality RNA production and formulation tools more accessible, helping researchers accelerate the development of next-generation RNA applications.”
Together, the companies aim to equip researchers with RNA production and formulation technologies that reduce technical barriers and accelerate progress in RNA research and therapeutic development.
Europa Biosite (www.europabiosite.com) is a pan-European group of life science distributors providing researchers and biotechnology companies with access to a broad portfolio of research technologies and laboratory products. Through a coordinated network across Europe, the group combines central strategy with strong local expertise and established relationships within regional research communities. Backed by EQT Healthcare Growth, Europa Biosite continues to expand its European footprint through strategic acquisitions.
Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization. Quantoom Biosciences is a trade name of Phoenix Biosciences SA. For more information about Quantoom Biosciences, visit www.quantoom.com
